logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
ARCT
Arcturus Therapeutics Holdings Inc.
6.89
2 x 5.07
2 x 8.83
bid
ask
+
0.17
2.53%
2 @ 07:15 AM
7.40 +0.51 (7.40%)
Ytd12.40%
1y-46.96%
6.74
day range
7.08
5.85
52 week range
24.17
Open6.74Prev Close6.72Low6.74High7.08Mkt Cap195.83M
Vol413.72KAvg Vol410.62KEPS-2.83P/EN/AForward P/E-7.41
Beta2.64Short Ratio9.41Inst. Own90.16%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0750-d Avg7.71200-d Avg9.341yr Est79.47

ARCT News

benzinga.com
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target o

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with

Arcturus could halve the grid's electrical losses using its nano-infused copper
techcrunch.com
Arcturus could halve the grid's electrical losses using its nano-infused copper

The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a l

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the an

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
benzinga.com
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
benzinga.com
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday

Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they

This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
benzinga.com
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday
benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday

Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analy

This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga.com
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S
benzinga.com
B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Tar

B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:AR

Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews
benzinga.com
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews
benzinga.com
Citigroup Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $21

Citigroup analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lower
benzinga.com
Citigroup Maintains Neutral on Arcturus Therapeutics, Raises Price Target to $8

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

benzinga.com
Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $25

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overwei

Arcturus Therapeutics Q4 Earnings Assessment
benzinga.com
Arcturus Therapeutics Q4 Earnings Assessment

Earnings Scheduled For March 3, 2026
benzinga.com
Earnings Scheduled For March 3, 2026

Earnings Preview: Arcturus Therapeutics
benzinga.com
Earnings Preview: Arcturus Therapeutics
benzinga.com
Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

benzinga.com
Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $500M

Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits__________________________From time to

benzinga.com
Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral

benzinga.com
Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $72

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overwei
benzinga.com
HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with
benzinga.com
Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the an

Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For November 10, 2025
benzinga.com
Preview: Arcturus Therapeutics's Earnings

This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
benzinga.com
This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
benzinga.com
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12

HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) fro
benzinga.com
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12

Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Ne
benzinga.com
Where Arcturus Therapeutics Stands With Analysts

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
benzinga.com
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in c
benzinga.com
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers t

Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results
benzinga.com
Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings
benzinga.com
Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
Arcturus Announces Interim Results From Ongoing Phase 2 Clinical Trial Of ARCT-032, Investigational

ARCT-032 generally safe and well toleratedMeaningful trends of clinical activity observed via high r
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
benzinga.com
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stoc

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempu
benzinga.com
Forecasting The Future: 5 Analyst Projections For Arcturus Therapeutics
benzinga.com
HC Wainwright & Co. Assumes Arcturus Therapeutics at Buy, Announces Price Target of $60

HC Wainwright & Co. analyst Andrew S. Fein assumes Arcturus Therapeutics (NASDAQ:ARCT) with a
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gild

Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Othe
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Arcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
benzinga.com
Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $42

Wells Fargo analyst Yanan Zhu maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and
benzinga.com
Citigroup Maintains Buy on Arcturus Therapeutics, Raises Price Target to $49

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and

benzinga.com
Arcturus Therapeutics Q2 EPS $(0.34) Beats $(0.96) Estimate, Sales $28.301M Beat $22.435M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.34) per share which beat the an